308 related articles for article (PubMed ID: 16652344)
1. Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.
Bell J; Moran C; Blatt J
Pediatr Blood Cancer; 2008 Feb; 50(2):370-1. PubMed ID: 16652344
[TBL] [Abstract][Full Text] [Related]
2. Neuroblastoma found in a 4-year-old after rituximab therapy for opsoclonus-myoclonus.
Chang BH; Koch T; Hopkins K; Malempati S
Pediatr Neurol; 2006 Sep; 35(3):213-5. PubMed ID: 16939863
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.
Burke MJ; Cohn SL
Pediatr Blood Cancer; 2008 Mar; 50(3):679-80. PubMed ID: 16900484
[TBL] [Abstract][Full Text] [Related]
4. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome.
Leen WG; Weemaes CM; Verbeek MM; Willemsen MA; Rotteveel JJ
Pediatr Neurol; 2008 Sep; 39(3):213-7. PubMed ID: 18725071
[TBL] [Abstract][Full Text] [Related]
5. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses.
Ertle F; Behnisch W; Al Mulla NA; Bessisso M; Rating D; Mechtersheimer G; Hero B; Kulozik AE
Pediatr Blood Cancer; 2008 Mar; 50(3):683-7. PubMed ID: 17226843
[TBL] [Abstract][Full Text] [Related]
6. [Opsoclonus myoclonus ataxia syndrome in Israel].
Blumkin L; Lerman-Sagie T
Harefuah; 2010 Jan; 149(1):24-8, 63. PubMed ID: 20422836
[TBL] [Abstract][Full Text] [Related]
7. Opsoclonus-myoclonus and anti-Hu positive limbic encephalitis in a patient with neuroblastoma.
Morales La Madrid A; Rubin CM; Kohrman M; Pytel P; Cohn SL
Pediatr Blood Cancer; 2012 Mar; 58(3):472-4. PubMed ID: 21480475
[TBL] [Abstract][Full Text] [Related]
8. Opsoclonus-myoclonus in children associated or not with neuroblastoma.
Krug P; Schleiermacher G; Michon J; Valteau-Couanet D; Brisse H; Peuchmaur M; Sarnacki S; Martelli H; Desguerre I; Tardieu M
Eur J Paediatr Neurol; 2010 Sep; 14(5):400-9. PubMed ID: 20110181
[TBL] [Abstract][Full Text] [Related]
9. Ofatumumab for refractory opsoclonus-myoclonus syndrome following treatment of neuroblastoma.
Ketterl TG; Messinger YH; Niess DR; Gilles E; Engel WK; Perkins JL
Pediatr Blood Cancer; 2013 Dec; 60(12):E163-5. PubMed ID: 23813921
[TBL] [Abstract][Full Text] [Related]
10. Response to rituximab and prednisolone for opsoclonus-myoclonus-ataxia syndrome in a child with ganglioneuroblastoma.
Corapcioglu F; Mutlu H; Kara B; Inan N; Akansel G; Gürbüz Y; Topcu S
Pediatr Hematol Oncol; 2008 Dec; 25(8):756-61. PubMed ID: 19065442
[TBL] [Abstract][Full Text] [Related]
11. B cell depletion therapy for new-onset opsoclonus-myoclonus.
Pranzatelli MR; Tate ED; Swan JA; Travelstead AL; Colliver JA; Verhulst SJ; Crosley CJ; Graf WD; Joseph SA; Kelfer HM; Raju GP
Mov Disord; 2010 Jan; 25(2):238-42. PubMed ID: 20063398
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for opsoclonus myoclonus ataxia syndrome associated with neuroblastoma.
Sinha S; Sarin YK
Indian J Pediatr; 2014 Feb; 81(2):218-9. PubMed ID: 23625470
[No Abstract] [Full Text] [Related]
13. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Travelstead AL; Barbosa J; Bergamini RA; Civitello L; Franz DN; Greffe BS; Hanson RD; Hurwitz CA; Kalinyak KA; Kelfer H; Khakoo Y; Mantovani JF; Nicholson SH; Sanders JM; Wegner S
J Pediatr Hematol Oncol; 2006 Sep; 28(9):585-93. PubMed ID: 17006265
[TBL] [Abstract][Full Text] [Related]
14. The opsoclonus–myoclonus syndrome.
Sahu JK; Prasad K
Pract Neurol; 2011 Jun; 11(3):160-6. PubMed ID: 21551110
[TBL] [Abstract][Full Text] [Related]
15. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Travelstead AL; Longee D
Pediatrics; 2005 Jan; 115(1):e115-9. PubMed ID: 15601813
[TBL] [Abstract][Full Text] [Related]
16. [Opsoclonus-myoclonus syndrome in children with neuroblastoma: description of 3 cases].
Garus K; Balwierz W; Skowronek B; Szweda E; Kroczka S; Moryl-Bujakowska A
Przegl Lek; 2010; 67(6):427-9. PubMed ID: 21344775
[TBL] [Abstract][Full Text] [Related]
17. Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments.
Battaglia T; De Grandis E; Mirabelli-Badenier M; Boeri L; Morcaldi G; Barabino P; Intra C; Naselli F; Pistoia V; Veneselli E; Conte M
Eur J Paediatr Neurol; 2012 Mar; 16(2):192-5. PubMed ID: 21737325
[TBL] [Abstract][Full Text] [Related]
18. Successful use of tacrolimus for treatment-refractory neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: A case series.
Delap S; Shah N; Kuns O; Franklin B; Skeens MA
Pediatr Blood Cancer; 2024 Apr; 71(4):e30903. PubMed ID: 38321586
[TBL] [Abstract][Full Text] [Related]
19. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.
Rudnick E; Khakoo Y; Antunes NL; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Matthay KK
Med Pediatr Oncol; 2001 Jun; 36(6):612-22. PubMed ID: 11344492
[TBL] [Abstract][Full Text] [Related]
20. Opsoclonus-myoclonus syndrome attributable to hepatitis C infection.
Ertekin V; Tan H
Pediatr Neurol; 2010 Jun; 42(6):441-2. PubMed ID: 20472199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
